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and IL-1b production, which inhibits TGF-b
production and promotes antibody-induced
joint inflammation
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Abstract
Introduction: Toll-like receptor (TLR)4 promotes joint inflammation in mice. Despite that several studies report a
functional link between TLR4 and interleukin-(IL-)1b in arthritis, TLR4-mediated regulation of the complicated
cytokine network in arthritis is poorly understood. To address this, we investigated the mechanisms by which TLR4
regulates the cytokine network in antibody-induced arthritis.
Methods: To induce arthritis, we injected mice with K/BxN serum. TLR4-mediated pathogenesis in antibody-
induced arthritis was explored by measuring joint inflammation, cytokine levels and histological alteration.
Results: Compared to wild type (WT) mice, TLR4-/- mice showed attenuated arthritis and low interferon (IFN)-g,
IL-12p35 and IL-1b transcript levels in the joints, but high transforming growth factor (TGF)-b expression. Injection
of lipopolysaccharide (LPS) enhanced arthritis and exaggerated joint cytokine alterations in WT, but not TLR4-/- or
IL-12p35-/- mice. Moreover, STAT4 phosphorylation in joint cells and intracellular IL-12p35 expression in
macrophages, mast cells and Gr-1+ cells were detected in WT mice with arthritis and enhanced by LPS injection.
Therefore, IL-12p35 appears to act downstream of TLR4 in antibody-induced arthritis. TLR4-mediated IL-12
production enhanced IFN-g and IL-1b production via T-bet and pro-IL-1b production. Recombinant IL-12, IFN-g and
IL-1b administration restored arthritis, but reduced joint TGF-b levels in TLR4-/- mice. Moreover, a TGF-b blockade
restored arthritis in TLR4-/- mice. Adoptive transfer of TLR4-deficient macrophages and mast cells minimally altered
joint inflammation and cytokine levels in macrophage- and mast cell-depleted WT mice, respectively, whereas
transfer of WT macrophages or mast cells restored joint inflammation and cytokine expression. Gr-1+ cell-depleted
splenocytes partially restored arthritis in TLR4-/- mice.
Conclusion: TLR4-mediated IL-12 production by joint macrophages, mast cells and Gr-1+ cells enhances IFN-g and
IL-1b production, which suppresses TGF-b production, thereby promoting antibody-induced arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease that is characterized by persistent joint inflamma-
tion and destruction of cartilage and bone [1]. Despite
intensive investigation, the immune mechanisms of RA
remain unclear. Various types of immune cells, such as
lymphocytes, macrophages and neutrophils, are involved
in the development of joint inflammation [2]. Further-
more, a complex cytokine network is crucially impli-
cated in the pathogenesis of RA [2]. However, the
mechanism by which this complicated cytokines net-
work is regulated in RA is not understood.
Toll-like receptors (TLRs) play crucial roles in the
innate and adaptive immune systems by recognizing
pathogen associated molecular patterns (PAMP) and
damage associated molecular patterns (DAMP) [3].
TLR4, a prototype TLR, is complexed with MD-2 and
CD14, and binds to lipopolysaccharide (LPS) [4]. Upon
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ligand engagement, TLR4-mediated signals are induced
via toll-interleukin-1 receptor domain-containing adaptor
inducing IFN-g (TRIF) and myeloid differentiation factor
88 (MyD88) [5,6]. Several studies have demonstrated the
crucial role of TLR4 in the pathogenesis of RA in murine
arthritis models. TLR4 attenuated joint inflammation in
IL-1 receptor antagonist-knockout (IL-1rn-/-) and col-
lagen-induced arthritis (CIA) mouse models, depending
on MyD88 [7]. In a zymosan-induced arthritis model,
intra-articular injection of an endogenous TLR4 ligand
(tenascin C) promoted joint inflammation [8]. In patients
with RA, TLR4 expression is increased in synovial tissues
at both early and late stages compared to those with
osteoarthritis [9]. These findings suggest that TLR4-
mediated signals promote joint inflammation in murine
models and RA patients. With respect to the TLR4-
mediated pathogenesis of RA, TLR4 inhibition reduces
the severity of CIA and joint IL-1 expression [10], while
IL-1-induced joint inflammation depends on TLR4 acti-
vation [11], suggesting that IL-1 signaling is associated
with TLR4-mediated immune regulation in the joints.
However, the mechanism by which TLR4 regulates auto-
immune joint inflammation via IL-1b signals is unknown.
Among the various murine arthritis models, the K/BxN
serum transfer model is a suitable in vivo system for
exploration of the complex cellular and cytokine network
in the effector phase of antibody-induced arthritis [12].
Although several reports suggest the functional link
between TLR4 and IL-1b in the pathogenesis of RA,
Choe et al. suggest that TLR4-mediated signals play a cri-
tical role in joint inflammation in the K/BxN serum
transfer model, but do not depend on IL-□ production in
joint tissues [13]. Therefore, the mechanism by which
TLR4-mediated signals promote antibody-induced arthri-
tis by regulating the complicated cytokine network
(which includes IL-1b) in the joints remains unclear. To
address this issue, we explored how TLR4 mediated sig-
nals regulate the cytokine network in the joints during
antibody-induced arthritis. Here, in contrast to previous
reports, we demonstrate that TLR4-mediated signals reg-
ulate joint IL-1b and IFN-g production via IL-12 produc-
tion by macrophages, mast cells and Gr-1+ cells, which
suppresses TGF-b production. This TLR4-mediated reg-




C57BL/6 mice were purchased from the Orient Company
(Seoul, Korea). KRN TCR transgenic mice and NOD mice,
kind gifts from Drs. D. Mathis and C. Benoist (Harvard
Medical School, Boston, MA, USA) and the Institut de
Genetique et de Biologie Moleculaire et Cellulaire (Stras-
bourg, France), were maintained on a B6 background
(K/B). Arthritic mice (K/BxN) were obtained by crossing
K/B and NOD (N) mice. TLR4-/- mice were a generous
gift from Dr. S. Akira (Osaka University, Osaka, Japan).
IL-12p35-/- and IL-12Rb2
-/- mice were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). These
mice were bred and maintained under specific pathogen-
free conditions at the Clinical Research Institute, Seoul
National University (CRISNUH). Animal experiments
were approved by the Institutional Animal Care and Use
Committee at the CRISNUH.
Serum transfer, arthritis scoring, and histological
examination
Arthritic K/BxN mice were bled and sera were pooled.
Recipient mice were injected i.p. (intraperitoneally) with
150 μL of pooled K/BxN sera on Days 0 and 2 (except for
those used in two experiments to investigate the effects
of LPS on joint inflammation (100 μL)). Three to six
mice were used in each experimental group. Moreover,
the individual mouse number in each experimental group
was described in each figure legend in detail.
Ankle thickness was measured with calipers (Manostat,
Herisau, Switzerland). Joint swellings in individual limbs
were scored as follows: 0, no joint swelling; 1, swelling of
one finger joint; 2, mild swelling of a wrist or ankle; and
3, severe swelling of a wrist or ankle. Joint swelling scores
in four limbs were added up, which were expressed as
clinical indexes. To examine histological changes in joint
tissues, whole knee joints and hind paws were fixed in
10% formalin 10 days after K/BxN serum transfer, decal-
cified and embedded in paraffin. Sections were stained
with H&E. Histological alterations were estimated
according to criteria described previously [14]. Scores of
0 to 4 were given for joint inflammation based on the fol-
lowing criteria: 0, no inflammation; 1, slightly thickening
of the lining layer or some infiltrating cells in the sublin-
ing layer; 2, slightly thickening of the lining layer plus
some infiltrating cells in the sublining layer; 3, thickening
of the lining layer influx of cells in the sublining layer;
and 4, synovium highly infiltrated with many infiltration
of inflammatory cells in the intra- and peri-articular
areas. In addition, cartilage erosion was estimated on a
scale of 0 to 4: 0, no destruction; 1, minimal erosion in
single spots; 2, mild to moderate erosion in a limited
area; 3, extensive erosion; and 4, general destruction. The
evaluators were blinded for the experimental groups.
Preparation for total joint cells
To prepare total joint cells, whole joint and hind paws
were obtained from mice 10 days after K/BxN serum
transfer. After the skin was removed, the joints were
twisted with forceps. Tissues between twisted joints
were taken, and then articular surfaces of the joints
were scraped with sharp forceps in order to take the
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remaining joint cells. These joint tissues were harvested
in PBS, filtered in 40 μm cell strainer (SPL Life Sciences,
Pocheon, Korea), and then collected. Total joint cells
contained immune cells (70%) and non-immune cells
(30%) (see Additional file 1A). Furthermore, immune
cells consisted of various cell subsets (see Additional file
1B). For subset analysis, PE-conjugated anti-CD45.2
(isotype control; mouse IgG1,), PE-conjugated anti-c-
kit (isotype control; mouse IgG2b, ), PE-Cy5-conjugated
anti-mouse F4/80 (isotype control; mouse IgG2a, ),
FITC-conjugated anti-mouse Gr-1 (isotype control:
mouse IgG2b, ), PE-conjugated anti-mouse NK1.1 (iso-
type control; mouse IgG1), and PE-Cy5-conjugated anti-
mouse TCRb mAbs (isotype control; mouse IgG) were
used. These antibodies were purchased from BD Phar-
mingen (San Diego, CA, USA) except for anti-c-kit and
anti-F4/80 mAbs (e-Bioscience, San Diego, CA, USA).
Injection of LPS and recombinant cytokines
WT B6, TLR4-/- or IL-12p35-/- mice were injected i.p. with
5 μg of LPS (Sigma Chemical Co., St. Louis, MO, USA)
one day before K/BxN serum transfer. Recombinant (r)
mouse (m) IL-12, IFN-g and IL-1b were purchased from
R&D Systems (Minneapolis, MN, USA). Injection doses of
IL-12 and IFN-g were decided based on previous report
[15]. TLR4-/- mice were injected i.p. with 500 ng of rmIL-
12 or rmIL-1b dissolved in 300 μl of PBS one day before
and after K/BxN serum transfer (Days -1, +1). TLR4-/-
mice were then injected i.p. with rmIFN-g (400 ng in
300 μL of PBS) one day before K/BxN serum transfer.
Blockade of TGF-b in vivo using mAb
To block TGF-b in vivo, WT B6 mice were injected i.p.
with 100 μg of anti-TGF-b (R&D Systems) or control
rat IgG mAbs (R&D Systems) one day before and one,
three and five days after K/BxN serum transfer.
Real-time PCR analysis
cDNA, prepared as described previously [16], was ampli-
fied in reactions containing TaqMan Universal Master
Mix (Perkin-Elmer Biosystems, Wellesley, MA, USA), a
gene-specific TaqMan probe, forward and reverse pri-
mers, and water. Gene-specific PCR products were mea-
sured using an Applied Biosystems 7500 Sequence
Detection System (Perkin-Elmer Biosystems). The
expressions of individual cytokines were quantified by a
standard curve method and normalized to GAPDH
expression. The following primers and probes were
synthesized by Applied Biosystems (TagMan Predeve-
loped Assay Reagent): GAPDH, 4352339E; IFN-g (Mm
00801778 m1; TGF-b1, GCAACATGTGGAACTCTAC-
CAGAA (forward), GACGTCAAAAGACAGCC ACTCA
(reverse), and FAM-ACCTTGGTAACCGGCTGCT-
GACCC-TAMRA; IL-12p35, Mm 00434169 m1; IL-1b:
Mm 00434228 m1; IL-6: Mm 00446190 m1; TLR4 Mm
00445273 m1; HSP60: Mm 01289491 m1; HMGB-1: Mm
00849805 m1; fibronectin-1: Mm 01256744 m1.
Intracellular staining for IL-12 and T-bet
Joint cells obtained from mice with antibody-induced
arthritis, some of which had been injected with LPS, were
filtered with 40-μm MILLEX GV filters (SPL Life
Sciences, Seoul, Korea). In addition, spleen cells from
TLR4-/- mice were cultured with LPS (100 ng/ml) and/or
recombinant IL-12 (50 ng/ml) for 4 h. After washing,
these cells (1 × 106) were stained with PE-conjugated
anti-mouse c-kit (BD Pharmingen) or PE-cy5-conjugated
anti-mouse F4/80 (eBioscience) mAb (0.5 μg in 200 μL of
PBS) in the presence of anti-mouse 2.4G2 mAb (BD
Pharmingen) for 30 minutes at 4°C. Anti-2.4G2 mAb is
used to block immunoglobulin binding to FcgIII and
FcgII on the cells. To perform intracellular staining, the
cells were fixed and permeabilized with Cytofix/Cyto-
perm according to the manufacturer’s instructions (BD
Biosciences). Then, cells were stained with Alexa Fluor
647-conjugated anti-mouse IL-12p35 (BD Pharmingen)
or APC-cy7-conjugated anti-mouse T-bet (eBioscience)
mAb. Cells were analyzed using a FACS LSR II flow cyt-
ometer (BD Biosciences) and FlowJo software (Treestar,
Inc., San Carlos, CA, USA)
Enzyme-linked immunosorbant assay (ELISA)
Cytokine amounts were estimated in joint cell culture
supernatant. To measure the IL-12 levels, joint cells
were cultured with control peptide, MyD88 or TRIF
inhibitor (20 μM/ml, Invitrogen, Carlsbad, CA, USA) in
the presence of LPS for 24 h. ELISA kits for all cyto-
kines were obtained from BD Biosciences and used
according to the manufacturer’s instructions. Standard
curves were generated using purified rmIFN-g, IL-1b
and IL-12. The reaction was stopped with 3N hydro-
chloric acid, and the absorbance was measured at 450
and 570 nm.
Adoptive transfer experiments
To deplete Gr-1+ cells in vivo, 100 μg of anti-mouse Gr-1
mAb (BD Bioscience) was injected intravenously into WT
mice one and three days before sacrifice. To deplete
macrophages, 200 μL of liposomal vehicle (LV) and clo-
dronate liposomes were injected into a tail vein three days
before sacrifice. Clodronate liposomes were a gift from Dr.
N. van Rooijen (Vrije Univiersiteit, Amsterdam, The Neth-
erlands). WT mice were injected i.p. with compound 48/
80 (Sigma Chemical Co., St. Louis, MO, USA) twice per
day at the following doses to deplete mast cells: 0.5 mg/kg
Day 1, 1 mg/kg Day 2, 2 mg/kg Day 3, 3 mg/kg Day 4, and
4 mg/kg Day 5. Spleen cells (1 × 107) obtained from WT
B6 or Gr-1+ cell-depleted mice were adoptively transferred
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into TLR4-/- mice by intravenous injection one day before
K/BxN serum transfer.
Western blot analysis
Ten days after K/BxN serum transfer, total joint cells
were obtained from whole joint tissues and stimulated
with LPS or rmIL-12 for 24 h. Proteins were eluted
from these cells using extraction reagent (GenDepot,
Barker, TX, USA), and Western blot analysis was per-
formed as described previously [17]. The blots were sub-
sequently incubated with rabbit anti-mouse pro-IL-1b,
mouse anti-mouse STAT4, anti-pSTAT4 or anti-b-actin
mAb (Cell Signaling Technology, Beverly, MA, USA).
Proteins were visualized using an LAS-4000 Mini ima-
ging system (Fujifilm Co., Tokyo, Japan).
Statistical analysis
Statistical significance was analyzed using Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA). A t-test
was used to compare pairs of groups and one-way
ANOVA followed by a Tukey’s test was used. For all
analyses, a P-value of < 0.05 was considered significant.
Results
TLR4-mediated signaling promotes antibody-induced
arthritis
To correlate joint TLR4 expression and antibody-
induced arthritis, the expression of TLR4 and its endo-
genous ligands were analyzed in the joints of WT mice
with antibody-induced arthritis by real-time PCR. TLR4
was constitutively expressed in the joints. Its expression
gradually increased, peaked at Day 7, and thereafter gra-
dually decreased (Figure 1A). Consistent with the TLR4
expression pattern in the joints, expression of endogen-
ous TLR4 ligands, such as HSP60, HMGB1 and fibro-
nectin, were also increased in the joints of WT mice at
Day 7 after K/BxN serum transfer (Figure 1B). These
findings suggest that TLR4 expression in the joints may
be involved in the pathogenesis of antibody-induced
arthritis. Therefore, to investigate whether TLR4 signal-
ing affects the development of antibody-induced arthri-
tis, we assessed joint inflammation in WT and TLR4-/-
mice after K/BxN serum transfer. WT mice showed
measurable joint swelling four to five days after K/BxN
serum transfer. This swelling peaked at 9 to 10 days
after serum transfer. In contrast, TLR4-/- mice were
resistant to the development of joint inflammation until
Day 6 and showed mild ankle swelling 6 to 10 days after
K/BxN serum transfer (Figure 1C). Maximum joint
swelling was much lower in TLR4-/- mice than WT
mice (Figure 1C, D). Histological examination of the
ankle joints of WT mice at Day 7 revealed significant
infiltration of inflammatory cells in the joints, whereas
TLR4-/- mice showed mild inflammatory cell infiltration
in the ankle joints (Figure 1D). To investigate LPS-
mediated TLR4 signaling in antibody-induced arthritis,
we injected WT mice with an amount of K/BxN serum
that resulted in sub-maximal joint swelling because LPS
injection did not alter full-blown arthritis in WT mice
(Figure 1C, E). Injection of LPS into WT mice exacer-
bated joint swelling during antibody-induced arthritis,
but it did not alter joint inflammation in TLR4-/- mice
(Figure 1C). These results indicate that the regulation of
arthritis by LPS-mediated signals is dependent on the
degree of joint inflammation and TLR4 signaling may
play a crucial role in the development and progression
of antibody-induced arthritis.
TLR4-mediated IL-12 production promotes antibody-
induced arthritis
To explore the mechanism by which TLR4 signals pro-
mote antibody-induced arthritis, we measured mRNA
expression of various cytokines in the joint tissues of
TLR4-/- and WT mice, some of which had been injected
with LPS, 10 days after K/BxN serum transfer. Joint TGF-
b transcript levels were higher in TLR4-/- mice than WT
mice, whereas TLR4-/- mice showed lower joint IFN-g,
IL-12p35 and IL-1b transcript levels than WT mice. In
WT mice, LPS injection increased IFN-g, IL-12p35 and
IL-1b transcript levels in the joints, but reduced TGF-b □
transcript levels. In contrast, TLR4-/- mice did not show
altered cytokine expression in the joints as a result of LPS
injection during antibody-induced arthritis (Figure 2A).
IL-6 levels in joint tissues were similar in the two groups
of mice during antibody-induced arthritis. These findings
suggest that TLR4 promotes antibody-induced arthritis by
regulating pro-inflammatory and anti-inflammatory cyto-
kine production in the joints.
Western blotting experiments revealed that joint cells
obtained from WT mice injected with LPS showed
increased phosphorylation of STAT4, a transcription fac-
tor crucial for IL-12 function, as compared with cells
obtained from WT mice (Figure 2B). These findings sug-
gest that TLR4-mediated signals enhance IL-12 produc-
tion in the joints during antibody-induced arthritis.
Furthermore, MyD88 and TRIF inhibitors inhibited LPS-
induced production of IL-12p35 in joint cells from WT
mice with arthritis as compared with cells treated with a
control peptide, indicating that LPS-mediated IL-12p35
production during antibody-induced arthritis depends on
MyD88 and TRIF (Figure 2C). Moreover, a previous
study demonstrated that IL-12p35 promotes antibody-
induced arthritis by respectively enhancing and suppres-
sing the production of IFN-g and TGF-b in the joints
[15]. Therefore, we hypothesized that IL-12p35 acts
downstream of TLR4 to regulate the cytokine network in
antibody-induced arthritis. To address this hypothesis,
we compared WT and IL-12p35-/- mice in terms of joint
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swelling and cytokine production in the presence or
absence of LPS during antibody-induced arthritis. In con-
trast to WT mice, administration of LPS to IL-12p35-/-
mice altered neither joint swelling nor IL-1b, IFN-g or
TGF-b transcript levels in the joints (Figure 2D, E).
Collectively, these data indicate that LPS-induced TLR4
signals promote antibody-induced arthritis by inducing
the production of IL-12p35 in the joints, which may reg-
ulate the complex cytokine network in the joints.
TLR4-mediated IL-12 production enhances IL-1b and
IFN-g production in the joints, which suppresses
TGF-b production, and thereby promotes
antibody-induced arthritis
Next, to investigate whether TLR4-mediated IL-12p35
production regulates IFN-g and IL-1b production in the
joints during antibody-induced arthritis, spleen cells were
obtained from WT and IL-12Rb2
-/- mice, and cultured
with LPS and/or recombinant IL-12 in vitro (Figure 3A,
C). Both LPS and recombinant IL-12 increased the pro-
duction of IFN-g and IL-1b by WT spleen cells. LPS-
mediated IL-1b and IFN-g production by spleen cells was
further enhanced by recombinant IL-12. In IL-12Rb2-defi-
cient spleen cells, recombinant IL-12 did not alter the pro-
duction of both IL-1b and IFN-g, while LPS alone
increased IL-1b production. Consistent with these results,
injection of LPS or recombinant IL-12 increased T-bet
expression in joint cells from WT mice with arthritis com-
pared with those from non-LPS-treated WT mice. Co-
stimulation of LPS and recombinant IL-12 produced an
even greater response (Figure 3B). Furthermore, recombi-
nant IL-12 increased T-bet expression in spleen cells from
TLR4-/- mice in the presence or absence of LPS, whereas
LPS did not affect T-bet expression. Pro-IL-1b is induced
by TLR signaling (signal 1), cleaved into IL-1b by caspase-
1 activity (signal 2) in the cytoplasm of immune cells, and
secreted as an active protein [18]. Western blotting
revealed that recombinant IL-12 increased pro-IL-1b
expression in joint cells from WT mice with arthritis in
the presence or absence of LPS, suggesting that TLR4-
mediated IL-12 regulates the production of pro-IL-1b in
joint cells, rather than its cleavage (Figure 3D). These
results suggest that TLR4-mediated IL-12 production
increases the production of both IFN-g and IL-1g in the
joints during antibody-induced arthritis.
To confirm the functional involvement of individual
cytokines in TLR4-mediated arthritis, we injected i.p.
recombinant IFN-g, IL-12 or IL-1b into TLR4-/- mice
during antibody-induced arthritis. Injection of recombi-
nant IFN-g, IL-12 or IL-1b into TLR4-/- mice restored
arthritis as compared to WT mice (Figure 4A), indicating
that these pro-inflammatory cytokines contribute to the
Figure 1 TLR4 promotes antibody-induced arthritis. (A) Toll-like receptor (TLR)4 transcript levels were measured in the ankle joint tissues of
wild type (WT) mice 0, 3, 5, 7, 8, 9 and 10 days after K/BxN serum injection (100 μL, twice) by real-time PCR (n = 5). (B) Levels of transcription of
endogenous TLR4 ligands were estimated in the ankle joint tissues of WT mice zero and seven days after K/BxN serum transfer (100 μL, twice)
by real-time PCR (n = 4). (C) Ankle thickness and clinical scores were measured in WT and TLR4-/- mice, some of which had been injected with
LPS, after K/BxN serum transfer (100 μL, twice) (n = 6). (D) Gross and histological examination of ankle joints in WT and TLR4-/- mice seven days
after serum transfer (n = 3), which was scored. (E) Ankle thickness and clinical scores were measured in WT mice, some of which had been
injected with LPS, after K/BxN serum transfer (150 μL of serum, twice) (n = 5). The results shown are representative of three repeated
independent experiments. n.s., not significant; * P < 0.05, ** P < 0.01, *** P < 0.001.
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pathogenesis of TLR4-mediated joint inflammation in
antibody-induced arthritis. Consistent with the results of
our in vitro experiments (Figure 3A-D), recombinant
IL-12 increased the expression of IFN-g and IL-1b in the
joints of TLR4-/- mice with arthritis, whereas neither
recombinant IL-1b nor IFN-g altered joint IL-12p35
expression levels (Figure 4B). These findings suggest that
IL-12p35 acts upstream of IL-1b and IFN-g in the joints
during antibody-induced arthritis. Meanwhile, the
administration of recombinant IL-1b, IL-12 or IFN-g to
TLR4-/- mice reduced TGF-b transcript levels in the
joints during antibody-induced arthritis, indicating that
these pro-inflammatory cytokines inhibit joint TGF-b
production (Figure 4B). Furthermore, anti-TGF-b mAb-
induced TGF-b blockade in TLR4-/- mice increased joint
swelling and IL-1b, IL-12p35 and IFN-g mRNA levels in
the joints (Figure 4A, B), indicating that TGF-b produc-
tion suppresses joint inflammation in TLR4-/- mice.
Figure 2 TLR4-mediated IL-12 production by joint cells promotes antibody-induced arthritis. To induce antibody-induced arthritis, mice
were injected with K/BxN serum (100 μL) twice (A, B, D, E). (A) interferon (IFN)-g, transforming growth factor (TGF)-b, interleukin(IL)-12p35, IL-1b,
and IL-6 transcript levels were measured in the joints of wild type and TLR4-/- mice, which had been injected with lipopolysaccharide (LPS), 10
days after serum injection (100 μL of serum, twice) by real-time PCR (n = 4). LPS (5 μg/300 μL in phosphate-buffered saline (PBS)) was injected
intraperotineally (i.p.) one day prior to K/BxN serum transfer. (B) STAT4 and phospho-STAT4 expression in joint cells from WT mice, some of
which had been injected with LPS, as analyzed by Western blotting. (C) Joint cells from WT mice with arthritis were incubated with LPS and a
control peptide, MyD88 or TRIF inhibitor, and IL-12 levels were measured in culture fractions. (D) Ankle thickness and clinical scores were
measured in WT and IL-12p35-/- mice, some of which had been injected with LPS (5 μg in 300 μL of PBS) in the K/BxN serum transfer model
(n = 6). (E) IL-4, IFN-g, TGF-b, IL-12p35, IL-1b and IL-6 transcript levels were measured in the joints of WT and IL-12p35-/- mice, some of which
had been injected with LPS (5 μg in 300 μL of PBS) 10 days after K/BxN serum transfer by real-time PCR (n = 6). The results shown are
representative of three repeated independent experiments. n.s., not significant; * P < 0.05, ** P < 0.01, *** P < 0.001.
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It further appears that TLR4-mediated signals regulate
joint inflammation by altering the balance between TGF-
b and pro-inflammatory cytokine production in the
joints. Taken together, these findings suggest that TLR4-
mediated IL-12 production enhances joint production of
IL-1b and IFN-g, which suppresses TGF-b production
and, thereby, promotes antibody-induced arthritis.
TLR4-mediated IL-12 production by macrophages and
mast cells plays a crucial role in promoting antibody-
induced arthritis, whereas Gr-1+ cells partially contribute
to TLR4-mediated joint inflammation
To determine whether joint immune cells produce IL-12
via TLR4 signals during arthritis, we performed intracel-
lular staining for IL-12p35 in joint macrophages and
mast cells from WT mice with antibody-induced arthri-
tis, some of which had been injected with LPS. Among
the different joint immune cells, macrophages and mast
cells that express TLR4 are crucial in the development of
antibody-induced arthritis [19,20]. Intracellular staining
and flow cytometric analysis revealed that IL-12p35 was
produced by macrophages and mast cells from WT mice
with arthritis, and that this production was enhanced by
LPS injection (Figure 5A). Next, to confirm the function
of macrophages and mast cells in TLR4-mediated regula-
tion of arthritis, we transferred macrophages and mast
cells from WT or TLR4-/- mice into macrophage- and
mast cell-depleted WT mice, respectively. In WT mice,
depletion of macrophage or mast cells attenuated anti-
body-induced joint inflammation and reduced IFN-g,
Figure 3 TLR4-mediated IL-12 production enhances joint IFN-g and IL-1b production in antibody-induced arthritis. (A and C) Spleen
cells from WT or interleukin(IL)-12Rb2-/- mice were stimulated with LPS and/or recombinant IL-12, and amounts of IFN-g and IL-1b were
measured in the culture fraction by ELISA. (B) Intracellular T-bet expression was measured in joint cells from WT mice, some of which had been
stimulated with LPS and/or recombinant IL-12, by flow cytometry. In addition, spleen cells from TLR4-/- mice were stimulated with LPS and/or
recombinant IL-12. (D) Joint cells from WT mice with antibody-induced arthritis were stimulated with LPS and/or recombinant IL-12. Western
blotting was performed to measure amounts of pro-IL-1b in these joint cells as compared with b-actin levels. The results shown are
representative of three repeated independent experiments. n.s. not significant; * P < 0.05, ** P < 0.01, *** P < 0.001.
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IL-12 and IL-1b expression in the joints, but increased
joint TGF-b expression. Adoptive transfer of WT macro-
phages or mast cells reversed these changes (Figure 5C,
E). However, TLR4-deficient macrophages and mast cells
did not alter joint inflammation or cytokine expression in
joint tissues in these mice (Figure 5B, D). Consistent with
these results, adoptive transfer of macrophage- (MD) or
mast cell-depleted (MsD) WT spleen cells into TLR4-/-
mice did not restore antibody-induced arthritis or cyto-
kine production in the joints, whereas non-depleted
WT spleen cells fully restored arthritis in TLR4-/- mice
(Figure 6A, B). Gr-1+ cell-depleted spleen cells partially
restored joint inflammation, indicating that Gr-1+ cells
partly contribute to the TLR4-mediated pathogenesis of
arthritis. Nevertheless, flow cytometric analysis revealed
that joint Gr-1+ cells in WT mice with antibody-induced
arthritis expressed intracellular IL-12p35, whose levels
were increased by the injection of LPS (Figure 6C).
Taken together, these results suggest that TLR4-
mediated IL-12 production by macrophages, mast cells
and Gr-1+ cells enhances joint production of IFN-g and
IL-1b, which suppresses TGF-b production, and thereby
promotes antibody-induced arthritis.
Discussion
Several studies have demonstrated that TLR4-mediated
signals induce macrophages, dendritic cells and synovial
cells from RA patients to produce IL-12 in vitro [21-23],
indicating that TLR4-mediated signals induce IL-12 pro-
duction by various immune and non-immune cells. More-
over, another study demonstrated that an IL-12p35/IFN-g
axis promotes antibody-induced joint inflammation by
suppressing TGF-b production in joint tissues [15]. These
findings led us to hypothesize that a TLR4-mediated
IL-12p35/IFN-g axis regulates antibody-induced arthritis
by suppressing TGF-b production. Consistent with this
Figure 4 Joint IFN-g and IL-1b production via TLR4-mediated IL-12 production suppresses TGF-b production, thereby promoting
antibody-induced arthritis. (A) Toll-like receptor (TLR)4-/- mice were injected intraperitoneally (i.p.) with recombinant interleukin (IL)-12, IL-1b
(500 ng in 300 μL of PBS), interferon (IFN)-g (400 ng in 300 μL of phosphate-buffered saline (PBS)) or anti-transforming growth factor (TGF)-b1
mAb (100 μg in 300 μL of PBS), one and three days prior to, and one day after K/BxN serum transfer (150 μL, twice). Clinical scores and ankle
thickness were monitored in these mice and compared with those in TLR4-/- and wild type (WT) mice (n = 4). (B) IFN-g, TGF-b, IL-12p35 and IL-
1b transcript levels were measured in the joint tissues of WT and TLR4-/- mice, and TLR4-/- mice injected with recombinant IL-12, IL-1b, IFN-g or
anti-TGF-b1 mAb (n = 4). The results shown are representative of three repeated independent experiments. n.s., not significant; * P < 0.05, ** P <
0.01, *** P < 0.001.
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Figure 5 TLR4-mediated IL-12 production by joint macrophages and mast cells plays crucial roles in promoting antibody-induced
arthritis. To induce antibody-induced arthritis, mice were injected with K/BxN serum (150 μL) twice (A-E). (A) Intracellular interleukin(IL)-12
expression was estimated in c-kit+ mast cells and F4/80+ macrophages from wild type (WT) mice, some of which had been injected with
lipopolysaccharide (LPS) 10 days after K/BxN serum transfer. (B and C) Macrophages from WT or Toll-like receptor (TLR)4-/- mice were adoptively
transferred into macrophage-depleted WT mice with antibody-induced arthritis. (D and E) Mast cells from WT or TLR4-/- mice were adoptively
transferred into mast cell-depleted WT mice with antibody-induced arthritis. (B and D) Ankle thickness and clinical scores were measured. (C and
E) Interferon (IFN)-g, transforming growth factor (TGF)-b, IL)-12p35, and IL-1b transcript levels in the joints 10 days after K/BxN serum transfer
were measured by real-time PCR. The results shown are representative of three repeated independent experiments. n.s., not significant; * P <
0.05, ** P < 0.01, *** P < 0.001; B, C, D, and E, n = 3.
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hypothesis, our current experiments revealed that IFN-g,
IL-12p35 and IL-1b transcript levels in joint tissues
increased in WT mice compared with TLR4-/- mice fol-
lowing K/BxN serum transfer, whereas TGF-b transcript
levels decreased. These findings suggest that IL-1b in addi-
tion to the IL-12p35/IFN-g axis promotes TLR4-mediated
joint inflammation. Several lines of evidence in our experi-
ments suggest that IL-12 acts downstream of TLR4, trig-
gering the production of both IFN-g and IL-1b in joint
tissues during antibody-induced arthritis, but suppressing
TGF-b production. First, TLR4-/- mice produce minimal
amounts of IL-12p35 in their joints during antibody-
induced arthritis compared with WT mice. Moreover,
injection of recombinant IL-12 into TLR4-/- mice restored
joint inflammation. In vitro experiments revealed that LPS
induced IL-12 production by joint immune cells, a
response dependent on MyD88 and TRIF. Injection of
LPS into WT mice increased the phosphorylation of the
IL-12-inducing transcription factor STAT4 in joint
immune cells during antibody-induced arthritis. Collec-
tively, these findings suggest that TLR4-mediated signals
induce the production of IL-12 by joint immune cells dur-
ing antibody-induced arthritis. Second, injection of LPS
enhanced antibody-induced arthritis and the production
of IFN-g and IL-1b in the joints of WT mice, but not
IL-12p35-/- mice. Furthermore, injection of recombinant
IL-12 into TLR4-/- mice enhanced the production of IFN-g
and IL-1b in the joints during antibody-induced arthritis,
whereas recombinant IFN-g and IL-1b did not enhance
IL-12p35 production. Moreover, LPS-induced production
of IL-12 by joint immune cells increased IFN-g and IL-1b
production by enhancing T-bet expression and pro-IL-1b
production. These findings suggest that TLR4-mediated
IL-12 production enhances the production of both IL-1b
and IFN-g in the joints during antibody-induced arthritis.
However, that IL-12 induces IL-1b production by enhan-
cing pro-IL-1b production during joint inflammation has
not previously been reported. Third, injection of recombi-
nant IFN-g, IL-1b or IL-12 into TLR4-/- mice reduced
TGF-b production in joint tissues during antibody-
induced arthritis, while a TGF-b blockade restored anti-
body-induced arthritis in TLR4-/- mice. These findings
Figure 6 Gr-1+ cells contribute to TLR4-mediated pathogenesis in antibody-induced arthritis. To induce antibody-induced arthritis, mice
were injected with K/BxN serum (150 μL) twice (A-C). (A) Toll-like receptor (TLR)4-/- mice were adoptively transferred with spleen cells (spc) from
wild type (WT) mice some Gr-1+ cell- (GD), macrophage- (MD), and mast cell- (MsD) depleted, one day prior to K/BxN serum transfer. Ankle
thickness and clinical scores were monitored in each group and compared with those in wild type (WT) and TLR4-/- (TLR4-/-) mice (n = 3). (B)
Interferon (IFN)-g, transforming growth factor (TGF)-b, interleukin (IL)-12p35 and IL-1b transcript levels in the joints of each group 10 days after
K/BxN serum transfer (n = 3) were measured by real-time PCR. (C) Intracellular IL-12 expression in Gr-1+ cells from WT mice, some of which had
been injected with LPS, was measured 10 days after K/BxN serum transfer (n = 3). The results shown are representative of three repeated
independent experiments. n.s., not significant; * P < 0.05, ** P < 0.01, *** P < 0.001.
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indicate that TLR4-mediated IL-12/IL-1b and IL12-/IFN-g
axes in the joints suppress TGF-b production, thereby
promoting antibody-induced arthritis. As no previous
reports have addressed functional links between TLR4 and
IL-12 regulatory axes in the pathogenesis of antibody-
induced arthritis, this study provides the first demonstra-
tion that TLR4-mediated IL-12 promotes arthritis by regu-
lating the production of both IL-1b and IFN-g, thereby
suppressing TGF-b production.
It has been suggested that TLR4-mediated signals pro-
mote joint inflammation by increasing levels of either
IL-17 or IL-1b in murine arthritis models [10,11,24,25].
However, WT and IL-17-/- mice showed similar joint
inflammation and cytokine production in the K/BxN
serum transfer model [15], suggesting that IL-17 may
have minimal involvement in the TLR4-mediated regula-
tion of antibody-induced arthritis. With regard to IL-1b,
Choe et al. suggested that TLR4 regulation of joint
inflammation bypasses the need for IL-1, although TLR4
and IL-1R play crucial roles in promoting antibody-
induced arthritis [13]. In their experiments, IL-1R-/- mice
showed attenuated arthritis compared with WT mice
upon K/BxN serum transfer, while LPS injection did not
alter joint inflammation in IL-1R-/- or WT mice. Based
on these findings, they suggested that LPS-mediated
TLR4 signals do not regulate joint inflammation in WT
or IL-1R-/- mice. In contrast to their results, our experi-
ments demonstrated that injection of WT mice with LPS
aggravated arthritis, when sub-maximal joint swelling
was induced by injection of an appropriate amount of
K/BxN serum, whereas LPS did not alter full-blown
arthritis in WT mice (Figure 1E), a result consistent with
the results of Choe et al. These findings suggest that
LPS-mediated TLR4 signals regulate antibody-induced
arthritis, depending on the severity of joint inflammation,
which might also account for contradictory results that
TLR4-/- mice showed K/BxN serum-induced arthritis
comparable to WT mice [26], although these divergent
findings should be further investigated. Therefore, we do
not completely rule out the possibility that IL-1b contri-
butes to TLR4-mediated pathogenesis in antibody-
induced arthritis. Consistent with this suggestion, Ji et al.
demonstrated that joint IL-1b expression levels were sig-
nificantly increased three to six days after K/BxN serum
transfer and suggested that IL-1 and TNF-b play critical
roles in antibody-induced arthritis [25]. Furthermore, our
experiments demonstrated that recombinant IL-1b
restored joint inflammation in TLR4-/- mice, indicating
that IL-1b promotes antibody-mediated joint inflamma-
tion, depending on TLR4-mediated immune responses.
Our data indicate that monocytes from HCV patients
are activated in vivo. This interferes with their differentia-
tion into DC, leading to deficient TLR4 signaling in these
cells that are enable to induce a Th1 response. This speci-
fic defect is linked to the activation of the MEK/ERK
pathwayTLR4 is expressed not only in joint-infiltrating
immune cells, but also in non-hematopoietic joint tissues,
and regulates joint inflammation by mediating the produc-
tion of various cytokines [27,28]. Several studies have
reported that macrophages, mast cells, NKT cells and
Gr-1+ cells play crucial roles in antibody-induced arthritis,
and express TLR4 on the cell surface [16,17,19,20,29]. Our
experiments demonstrated that adoptive transfer of WT
mast cells or macrophages fully restored joint inflamma-
tion in macrophage- and mast cell-depleted WT mice,
respectively, indicating that TLR4-expressing macrophages
and mast cells, rather than non-hematopoietic joint cells,
are crucial to antibody-induced arthritis. However, adop-
tive transfer of Gr-1+ cell-depleted spleen cells only par-
tially restored joint inflammation in TLR4-/- mice,
indicating that Gr-1+ cells contribute less significantly to
the promotion of antibody-induced arthritis via TLR4-
mediated signals than macrophages and mast cells,
although Gr-1+ cells play a crucial role in the development
of joint inflammation. With respect to NKT cells, our
recent study clearly demonstrated that invariant NKT cells
express TLR4, which promotes antibody-induced arthritis
[30], although the expression patterns of TLR4 in NKT
cells are controversial [31-33]. Therefore, macrophages,
mast cells, Gr-1+ cells and invariant NKT cells promote
antibody-induced arthritis by expressing TLR4. Further-
more, levels of TLR4, which was constitutively expressed
in the joints, gradually increased, peaked, and then gradu-
ally decreased in our current experiments. Consistent with
the TLR4 expression pattern in the joints, levels of the
endogenous TLR4 ligands HSP60, HMGB1 and fibronec-
tin were also increased in the joint tissues of WT mice
during antibody-induced arthritis. Moreover, antibody-
induced arthritis was developed in WT, but not in TLR4-/-
mice in the absence of exogenous TLR4 ligand, indicating
that TLR4 endogenous ligands contribute to developing
antibody-induced arthritis. Therefore, TLR4 on immune
cells may be engaged by endogenous or exogenous ligands,
which induce TLR4-mediated downstream immunological
events. Consistent with our results, levels of endogenous
TLR4 ligands, including HMGB-1, s100 proteins and hya-
luronic acid were found to be elevated in the synovial fluid
or serum of RA patients [34], and concentrations were
correlated with clinical scores in RA patients [35].
For therapeutic purposes, it would be beneficial to inhi-
bit TLR4 signals, IL-12 production, and the effects of IL-
12 on IL-1b and IFN-g production in antibody-induced
joint inflammation. Several studies have demonstrated that
anti-IL-12 mAbs ameliorate CIA in mice [36,37], suggest-
ing that a blockade of IL-12 with a neutralizing mAb may
be a useful therapeutic strategy for rheumatoid arthritis.
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Alternatively, strategies to block the functional activity of
TLR4-expressing effector cells may also be helpful in treat-
ing rheumatoid arthritis.
Conclusions
Our experiments suggest that TLR4-mediated signals
activated by endogenous or exogenous ligands induce
the production of IL-12 by macrophages, mast cells and
Gr-1+ cells, which enhance IL-1b and IFN-g production,
thereby suppressing TGF-b production. This TLR4-
mediated regulation of the cytokine network promotes
antibody-induced arthritis. These findings may facilitate
the development of new TLR4-targeted therapeutic stra-
tegies to inhibit rheumatoid arthritis.
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Additional file 1: Subset analysis for joint cells from mice with
antibody-induced arthritis. Total joint cells were obtained from WT
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isotype-matched control. (B) Subset analysis for total joint cells was
performed.
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